ler bank
- After the US FDA pushed back its trial design plans, Akebia Therapeutics (NASDAQ:AKBA) has decided to abandon its efforts to expand the indication of Vafseo (vadadustat) to treat anemia in chronic kidney failure patients not on dialysis. Actions
